Document Detail

Gestational trophoblastic disease metastatic to the brain.
MedLine Citation:
PMID:  8657926     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate clinical characteristics, treatment technique, and results in patients with gestational trophoblastic disease metastatic to the brain. MATERIALS AND METHODS: From 1962 to 1994, 26 (4.1%) of 631 patients who underwent treatment for trophoblastic disease had or developed evidence of brain metastases (patients were aged 14-43 years). All patients received multiagent systemic chemotherapy and whole-brain irradiation. Total doses of radiation were 2,386-4,000 cGy (200-300 cGy per fraction). No patient received intrathecal chemotherapy. Patients were divided into three groups: group A, symptomatic brain metastases at presentation; group B, asymptomatic or minimally symptomatic brain disease at presentation; and group C, development of brain metastases during systemic chemotherapy. RESULTS: The overall 5-year actuarial survival rate was 51%. Multivariate analysis findings indicated that age, preceding pregnancy event, human chorionic gonadotropin level, World Health Organization score, performance of craniotomy, and number of brain metastases did not influence survival. The difference in the 5-year overall survival rates between groups A (39%) and B (100%) was significant (P = .03). CONCLUSION: Gestational trophoblastic disease metastatic to the brain is curable with systemic chemotherapy and whole-brain irradiation. The authors suggest treatment with steroids, chemotherapy (etoposide, high-dose methotrexate [1 g/m2], dactinomycin, cyclophosphamide, and vincristine sulfate), and concurrent whole-brain irradiation (3,000 cGy in 200-cGy fractions).
W Small; J R Lurain; R M Shetty; C F Huang; G L Applegate; W N Brand
Related Documents :
22997596 - Primary renal lymphoma: long-term results of two patients treated with a chemotherapy +...
24823696 - Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therap...
9300736 - Tumor-related prognostic factors for remission of brain metastases after radiotherapy.
9128946 - Recursive partitioning analysis (rpa) of prognostic factors in three radiation therapy ...
2213106 - Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leu...
15305396 - Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Radiology     Volume:  200     ISSN:  0033-8419     ISO Abbreviation:  Radiology     Publication Date:  1996 Jul 
Date Detail:
Created Date:  1996-08-01     Completed Date:  1996-08-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0401260     Medline TA:  Radiology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  277-80     Citation Subset:  AIM; IM    
Division of Radiation Oncology, Robert H. Lurie Cancer Center, Chicago, IL 60611, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Brain Neoplasms / drug therapy,  radiotherapy,  secondary*
Combined Modality Therapy
Survival Rate
Trophoblastic Neoplasms / drug therapy,  mortality,  radiotherapy,  secondary*
Uterine Neoplasms / drug therapy,  pathology*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Heel spur: radiation therapy for refractory pain--results with three treatment concepts.
Next Document:  Breast-conserving surgery for primary breast cancer: necessity for surgical clips to define the tumo...